Evolent Health Inc

Evolent Health Inc(EVH)股票分析

$4.280

-0.209 (-4.89%)收盘时

Loading chart…
High
4.510
Open
4.450
VWAP
4.33
Vol
2.83M
Mkt Cap
2.30B
Low
4.215
Amount
12.27M
EV/EBITDA, TTM
-199,017.01

Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers primary solutions, including specialty care management services and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.

AI analysis of Evolent Health Inc (EVH)

hold

Evolent Health Inc is currently priced at $4.60, which is below the average analyst price target of $6. This suggests potential upside of approximately 30.43%. However, the stock has a forward P/E ratio of 25.91, indicating that it may be overvalued relative to its earnings potential. The recent RSI of 49.75 suggests the stock is neither overbought nor oversold, indicating a neutral momentum. The main risk is the high net debt-to-EBITDA ratio of 7x, which could pressure the company to raise capital under unfavorable conditions.

Analyst Ratings (13)

+117.99% upside
Buy
13 Buy
0 Hold
0 Sell
Current: 4.28
最低
5.00
平均
9.33
最高
16.00

Citi

2026-08-10

目标价

$6

Buy

Canaccord

2026-08-10

目标价

$6

Buy

TD Cowen

2026-07-28

目标价

$5

Buy

Citi

2026-07-23

目标价

Neutral

Canaccord

2026-07-21

目标价

$7

Buy

估值指标

The current forward P/E ratio for Evolent Health Inc (EVH) is 24.15, compared to its 5-year average forward P/E of 76.52.

Forward P/E

Fair
5Y Average P/E
76.52
Current P/E
24.15
高估
293.13
低估
-140.09

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
-1430.09
Current EV/EBITDA
-199017.01
高估
15534.24
低估
-18394.42

Forward P/S

Undervalued
5Y Average P/S
1.19
Current P/S
0.16
高估
1.92
低估
0.45

Alphio AI Price Scenarios for EVH

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%EVH

$10.23

情景价格

B

Base

Base · 50%EVH

$8.49

情景价格

B

Bear

Bear · 25%EVH

$7.28

情景价格

Whales holding EVH

R

Rock Springs Capital Management LP

+ HoldingEVH

+19.26%

3M Return

事件时间线

2026-08-06 (ET)

08:00:00

2026 Revenue Consensus at $2.5B, Adjusted EBITDA Guidance Tightened to $120M-$135M

08:00:00

Evolent Reports Q2 Revenue of $652.52M, Beating Consensus

2026-05-07 (ET)

07:30:00

Evolent Q1 Revenue at $496.25M, Below Consensus

2026-03-19 (ET)

09:00:00

Evolent Health Appoints Archie Mayani as Chief Product Officer

2026-03-02 (ET)

07:40:00

Oppenheimer Lowers Evolent Health Price Target to $6

资讯

EVH FAQ — answered by Alphio AI

Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers primary solutions, including specialty care management services and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner. It operates in the Healthcare sector (SERVICES-MANAGEMENT SERVICES industry).

Evolent Health Inc is currently priced at $4.60, which is below the average analyst price target of $6. This suggests potential upside of approximately 30.43%. However, the stock has a forward P/E ratio of 25.91, indicating that it may be overvalued relative to its earnings potential. The recent RSI of 49.75 suggests the stock is neither overbought nor oversold, indicating a neutral momentum. The main risk is the high net debt-to-EBITDA ratio of 7x, which could pressure the company to raise capital under unfavorable conditions.

13 analysts cover EVH: 13 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.33.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始